Premium
Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer
Author(s) -
Kim Jin Hwi,
Lee Joon Mo,
Ryu Ki Sung,
Lee Yong Seok,
Park Yong Gyu,
Hur Soo Young,
Lee Keun Ho,
Lee Sung Ha,
Kim Seung Jo
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21448
Subject(s) - medicine , paclitaxel , hyperthermic intraperitoneal chemotherapy , chemotherapy , epithelial ovarian cancer , ovarian cancer , laparotomy , debulking , oncology , surgery , cancer , gastroenterology , cytoreductive surgery
Background We evaluated the efficacy and feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) using paclitaxel as consolidation therapy in patients with epithelial ovarian cancer. Methods Between November 1999 and January 2004, 18 patients with a negative second‐look and 1 patient with positive peritoneal cytology only with stage Ic–IIIc epithelial ovarian cancer received consolidation intra‐operative HIPEC using paclitaxel. The HIPEC was performed with open‐abdomen technique, using 6 L of lactated Ringer's solution containing paclitaxel 175 mg/m 2 , for 90 min in hyperthermic phase (43–44°C). The survival rates were compared with 24 patients treated with conventional therapy (control group). Results The 8‐year progression‐free survival rates were 63.16% in the HIPEC‐paclitaxel group and 29.17% in the control group ( P = 0.027). The 8‐year overall survival rates were 84.21% in the HIPEC‐paclitaxel group and 25.00% in the control group ( P = 0.0004). The time interval between initial treatment and HIPEC was statistically significant with respect to progression‐free and overall survival in the HIPEC‐paclitaxel group. Conclusion HIPEC with paclitaxel during 2nd‐look laparotomy is feasible and relatively safe and showed a good effect on survival. In patients with epithelial ovarian cancer who have a complete pathologic response, HIPEC with paclitaxel should be considered as a consolidation treatment option. J. Surg. Oncol. 2010;101:149–155. © 2009 Wiley‐Liss, Inc.